Research progress in metformin for treatment of prostate cancer

After treating by androgen deprivation therapy (ADT) in patients with prostate cancer, the prostate cancer cells gradually adapt to low androgen environments, and condition of disease will inevitably evolve to castration resistant prostate cancer (CRPC). In recent years, studies have found that single or combined treatment with metformin (MF) may delay the development of prostate cancer in the middle-aged and elderly patients. This paper aimed to take a brief review of the research progress on the effect of MF on prostate cancer.